There were 124 press releases posted in the last 24 hours and 397,194 in the last 365 days.

Luupalabs launches Luupa to promote medication adherence, compliance and monitoring

Luupa unit

The full benefit of biologic therapies isn’t reached and quality of life is compromised if patients don’t adhere to their medication regimen

The greater the ignorance the greater the dogmatism.
— William Osler
SERI KEMBANGAN, SELANGOR, MALAYSIA, October 28, 2016 /EINPresswire.com/ -- Luupalabs today announced the launch of Luupa, a reminder device driven by technology that assists users to comply with medication adherence and compliance on Indiegogo.

Luupalabs aims to make it easier and more convenient for users to take their medications as prescribed. Luupa will be available in in stores and pharmacies throughout the world by March 2017.

Poor medication adherence presents a significant global problem. A World Health Organization (WHO) report found that global medication adherence among patients with chronic diseases averages 50 percent, and that the impact of poor adherence increases as the level of chronic disease increases.

Research shows that people with chronic diseases taking multiple medications may make numerous trips to the pharmacy each month for refills, which makes it harder for them to stay on track with different fill schedules and take them regularly as prescribed.

Luupa aims to address the issues above by providing a total solution for it's users from various walks of medical conditions who takes oral medication, external medication as well as diabetic users to make medication adherence and compliance easier as we help people on their path to better health.

Aliff Adam
Luupalabs
60132338592
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.